Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a WhatsApp message make you check your heart?

NCT ID NCT07879144

NEW Prevention Sponsor: Cardiovascular Advancement and Research Excellence Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 16, 2026 · Last updated Oct 16, 2026

Summary

Researchers in Malaysia are testing whether personalised WhatsApp messages can help people act on heart risk screening results. Adults screened at community NADI centres who have moderate or high cardiovascular risk join the study. Half receive standard risk feedback and referral letters, while the other half also get 90 days of tailored nudges, reminders, and barrier-solving messages. The trial tracks whether participants complete recommended checks like blood pressure, glucose, or lipid tests, or attend a doctor visit.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Personalised WhatsApp behavioural nudges
What this could lead to
If the nudges work, health systems could use cheap messaging to turn heart risk screening into real preventive action, such as blood tests and doctor visits.
What could go wrong
People may ignore messages, change phone numbers, or face clinic barriers that messages cannot fix. The trial measures actions like check-ups, not whether heart attacks or strokes are prevented.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 6,588 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Malaysian citizens * Aged 18 years or older * Classified as moderate (≥ 10% to \< 20%) or high (≥ 20%) cardiovascular risk by the Framingham Risk Score within the MyHeartRisk platform. * Participants classified as high risk without calculation of an FRS, within the high-risk stratum: * established atherosclerotic cardiovascular disease * diabetes mellitus with proteinuria or with a major risk factor such as smoking, hypertension or dyslipidaemia * ≥Stage 4 CKD * Able to provide their own or consenting carer/next-of-kin mobile number for follow-up * Has a WhatsApp-capable mobile phone (own or consenting carer/next of kin) * Willing to be contacted at Day 30 and Day 90 for study-related follow-up and outcome assessment. * Able to provide minimum required cardiovascular risk data, including age, sex, blood pressure, and smoking status * Able to provide informed consent in Bahasa Malaysia or English Exclusion Criteria: * Unable to provide minimum required data fields for MyHeartRisk calculation * No reliable contact number available for any form of follow-up * Acutely unwell at time of screening and requires immediate medical attention (these individuals should be directed to emergency services without delay). * Unable to understand study procedures and behavioural nudges in Bahasa Malaysia or English

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder diabetes mellitus Dyslipidemias hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular diseases Cardiovascular risk factor

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cardiovascular Advancement Research Excellence Institute (CARE Institute)

    Sungai Buloh, Selangor, 47000, Malaysia

  • National Information Dissemination Centre (NADI) and Malaysian Communications and Multimedia Commission (MCMC)

    Cyberjaya, Selangor, 63000, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.